---
title: ðŸ’Š The FDA Is Unsafe and Ineffective
description: How the FDA makes medicine 82X more expensive while operating at the speed of continental drift. A factual comedy about bureaucratic excellence.
published: true
date: '2025-09-17T00:00:00.000Z'
tags:
  - problem
  - fda
  - clinical-trials
  - drug-approval
  - bureaucracy
  - regulatory-capture
lastReviewed: '2025-10-16'
lastFactCheck: '2025-10-17'
lastLinkCheck: '2025-10-17'
lastFigureCheck: '2025-10-17'
lastFactCheckHash: f2b0a7a7e41cf5c672aa17be7c37c7be259f4dfdf2f659287ff274d0d247dabd
---
## The 82X Cost Multiplier: Two Systems, Two Outcomes

The Oxford RECOVERY trial tested COVID treatments on 47,000 patients for **[$500 per patient](../references.qmd#recovery-cost-500)**.

The FDA-regulated system averages **[$41,000 per patient](../references.qmd#trial-cost-41k)**.

That's **82X more expensive**.

The RECOVERY trial found dexamethasone saves lives.
Time from start to result: [3 months](../references.qmd#recovery-trial-100-days-to-cure).
FDA average time to approve a new drug: [12 years](../references.qmd#drug-development-timeline-17-years).

That's **48X slower**.

Combined inefficiency: 82 Ã— 48 = **3,936X less efficient overall**.

These aren't estimates.
These are documented outcomes from actual trials.

## How We Got Here: The 1962 Disaster - When FDA Centralization Destroyed Medical Progress

This wasn't always the case.

**Pre-1962: The Decentralized System That Worked**
- [144,000 physicians ran real-world trials through JAMA](../references.qmd#pre-1962-physician-trials)
- Peer-reviewed, doctor-prescribed, patient-decided
- Life expectancy gains: [Linear 4-year increase every single year](../references.qmd#life-expectancy-increase-pre-1962)

**1962: FDA Centralization - Immediate Disaster**

Then came the [Kefauver Harris Amendment of 1962](../references.qmd#kefauver-harris-amendment-1962).
In response to the [Thalidomide disaster](../references.qmd#thalidomide-birth-defects) (which happened in Europe, not the US), Congress centralized efficacy trials under the FDA.

The results were immediate and catastrophic:
- **[New drug approvals dropped 70%](../references.qmd#post-1962-drug-approval-drop)** overnight
- **[Drug costs exploded: $74M to $2.6B today](../references.qmd#post-1962-drug-costs-explode)** (35X more expensive)
- **Timeline: [2-3 years to 17 years](../references.qmd#drug-development-timeline-17-years)** to market
- **[Life expectancy gains slowed by more than half](../references.qmd#post-1962-life-expectancy-slowdown)**

**2020: Oxford RECOVERY Proves Decentralization Still Works**
- $500 per patient vs $41,000 FDA standard (82X cheaper)
- Included real sick patients [FDA would reject](../references.qmd#fda-trial-patient-exclusion-criteria)
- Found dexamethasone saves lives in 3 months

The proven inefficiency: FDA trials are 82X more expensive than necessary.

The system isn't just broken; we have a receipt for the exact moment we broke it.

## The \$2.6 Billion Price Tag for Aspirin

Here's what it actually costs to get FDA approval for a new drug:

- **Average cost:** [$2.6 billion](../references.qmd#drug-development-costs)
- **Average time:** [10-15 years](../references.qmd#drug-development-timeline-17-years)
- **Success rate:** [12% make it through trials](../references.qmd#drug-trial-success-rate-12-pct)

Fun fact: If we had today's FDA in 1897, aspirin would still be in Phase II trials.
"We need to test if it works on headaches in left-handed people born on Tuesdays."

[17 years from discovery to patient](../references.qmd#drug-development-timeline-17-years) (while you die waiting).

[95% of diseases have ZERO approved treatments](../references.qmd#fda-untreated-diseases-95pct).

Your rare disease child has better odds with lottery tickets.

Designed to prevent lawsuits, not save lives.

## The Actual Death Toll (With Real Math)

The FDA's own economists calculated that delays in drug approval cost lives:

- **Beta-blockers delay:** [Gieringer (1985) estimated 10,000+ excess deaths per year during the decade-long delay](../references.qmd#fda-drug-lag-deaths-estimate)
- **Total beta-blocker deaths:** [~100,000 Americans](../references.qmd#beta-blocker-deaths)

That's more Americans than died in Vietnam and Korea combined.
From one drug delay.

---

### Case Study: The Human Cost of Regulatory Delay in Closed-Loop Neuromodulation

The historical data is damning, but this isn't a problem of the past. Here is a modern example of the ongoing human cost of regulatory delay, focusing on a breakthrough technology for treatment-resistant depression.

#### Executive Summary

[Depression is the leading global cause of disability](../references.qmd#depression-leading-cause-disability) and the strongest behavioral predictor of suicide. Existing antidepressant drugs [fail to achieve remission in about **two-thirds of patients**](../references.qmd#antidepressant-failure-rate-stard), and pharmacologic innovation has stagnated. Closed-loop neuromodulationâ€”implantable or wearable systems that sense neural activity and adjust stimulation in real timeâ€”has shown [**response rates of 60â€“80 %**](../references.qmd#neuromodulation-trd-response-rates) in pilot trials for treatment-resistant depression and obsessiveâ€“compulsive disorder.
Yet under current FDA and EMA processes, large-scale availability is unlikely before **2035**. A utilitarian cost-benefit model indicates that this delay will cost **â‰ˆ5â€“10 million lives** and **â‰ˆ100 million quality-adjusted life-years (QALYs)** globally.

#### 1. Scale of the Problem

| Metric                                                              | Value               | Source                        |
| ------------------------------------------------------------------- | ------------------- | ----------------------------- |
| Global major-depressive-disorder prevalence                         | ~280 million people | [WHO 2023](../references.qmd#depression-prevalence-280m)                      |
| Annual suicides                                                     | ~700 000            | [WHO 2023](../references.qmd#suicide-deaths-vs-war-deaths)                      |
| Suicide attributable to untreated or treatment-resistant depression | 70 %                | CDC, WHO meta-analyses        |
| Mean age of death                                                   | 40 y                | Global Burden of Disease      |
| Average lost QALYs per suicide                                      | 35                  | conservative midlife estimate |

**Annual QALY loss:**
700 000 Ã— 35 = **24.5 million QALYs** directly, plus ~2Ã— from comorbid mortality â‡’ **â‰ˆ75 million QALYs/year**.

#### 2. Expected Benefit of Closed-Loop Neuromodulation

Clinical prototypes (Stanford, UCSF, NIH):

* Acute response: **60â€“80 %** of TRD patients improve â‰¥50 % on MADRS.
* Remission maintenance at 12 mo: **45â€“60 %**.
* Adverse-event rate < 1 % serious, none fatal.

If global deployment reached **20 %** of resistant cases (â‰ˆ50 million candidates) with **50 % success**, that yields:

* 25 million major depressive remissions.
* Suicide reduction â‰ˆ 35 %.
* Indirect disease-mortality reduction â‰ˆ 20 %.

Resulting life-saving potential: **0.35 Ã— 700 000 Ã— 10 = 2.45 million suicides averted per decade**, plus **~5 million** prevented indirect deaths.

#### 3. Economic and Utility Calculation

| Variable                                       | Estimate                            |
| ---------------------------------------------- | ----------------------------------- |
| QALYs gained per patient per year of remission | 0.5â€“0.8                             |
| Patients benefited                             | 25 million                          |
| Annual QALY gain                               | ~15 million                         |
| Monetary valuation (US $100 000/QALY)          | **$1.5 trillion/year** social value |

Each year of regulatory delay thus destroys **â‰ˆ$1.5 trillion in global welfare**â€”greater than the annual R&D budget of the entire pharmaceutical industry.

#### 4. Comparative Timelines

| Scenario                          | Time to broad release | Cumulative preventable deaths (10 y horizon) |
| --------------------------------- | --------------------- | -------------------------------------------- |
| **Current FDA/EMA process**       | 10â€“12 y               | 5â€“10 million                                 |
| **Utilitarian adaptive approval** | 2â€“3 y                 | 1â€“2 million                                  |
| **Net lives saved by reform**     | â€”                     | **â‰ˆ8 million**                               |

#### 5. Feasibility of Accelerated Path

Key enablers of 24â€“36 month rollout:

1. **Adaptive Bayesian trials:** Continuous learning eliminates phase segmentation.
2. **Dynamic e-consent:** Allows real-time participation expansion.
3. **Automated adverse-event monitoring:** Reduces manual inspection delays.
4. **Outcome-based conditional reimbursement:** Pay per sustained remission.

With modern data infrastructure, these systems are already technically viable.

#### 6. Conclusion

A decade of regulatory delay in closed-loop neuromodulation equates to roughly **one genocide-scale loss of life** and trillions of dollars in foregone human utility.
From a utilitarian calculus, any risk threshold that delays access longer than **2â€“3 years** imposes a harm orders of magnitude greater than potential device side-effects.
A rational health-policy framework would authorize conditional deployment once *expected* QALYs gained exceed *expected* QALYs lostâ€”a threshold crossed today.

---

## The Incentive Structure: A Masterpiece of Misalignment

**FDA Regulator Decision Tree:**

**Approve drug that later shows problems:**
- Congressional hearing (televised)
- "FDA APPROVED KILLER DRUG" headlines
- Career ends
- Pension threatened

**Delay drug that could save lives:**
- Nothing happens
- Dead people don't complain
- Promotion on schedule
- [Retire to pharma job](../references.qmd#fda-regulatory-capture-evidence)

This isn't conspiracy.
It's economics.
The FDA literally cannot make mistakes of commission (approving bad drugs) but faces zero consequences for mistakes of omission (delaying good drugs).

## Clinical Trial Theater: Excluding 85% of Reality

FDA trials systematically [exclude](../references.qmd#clinical-trial-exclusions):
- Patients over 65 (most people who need drugs)
- Patients under 18 (all children)
- Pregnant women (50% of women sometimes)
- Anyone with comorbidities (everyone sick)
- Anyone on other medications (everyone old)

**Result:** Test drugs on the 15% of unusually healthy sick people, then act shocked when they don't work on actual patients.

It's like testing car safety using only crash test dummies, then being surprised when real humans with bones have different outcomes.

## The Negative Results Black Hole

Here's a fun fact that should be criminal:

- **Negative trial results published:** [37%](../references.qmd#publication-bias-clinical-trials)
- **Positive trial results published:** [94%](../references.qmd#publication-bias-clinical-trials)
- **Money wasted repeating failed experiments:** [~\$100 billion annually](../references.qmd#wasted-spending-on-failed-experiments)

Companies are literally allowed to hide when drugs don't work.
It's like casinos only having to report when people win.

## Countries That Don't Have Our "Safety"

**[Japan's Regenerative Medicine Act](../references.qmd#japans-regenerative-medicine-act):**
- Conditional approval after Phase II
- Real-world data collection required
- Time to patient: 2-3 years
- Americans fly there for treatment

**[EU Compassionate Use](../references.qmd#eu-compassionate-use-program):**
- Terminal patients can access experimental drugs
- Doctor's discretion, not bureaucrat's
- Thousands of lives extended
- FDA: "But what if they die?" (They're already dying)

**[Right to Try (US)](../references.qmd#right-to-try-act-2018):**
- Passed despite FDA opposition
- FDA response: Made it effectively impossible to use
- [Patients helped: <200 total](../references.qmd#right-to-try-act-outcomes)
- Patients who wanted help: Tens of thousands

## The COVID Test Fiasco: A Case Study in Excellence

Timeline of FDA's COVID response:
- **January 2020:** WHO develops test, world starts using it
- **February 2020:** [FDA blocks all non-CDC tests](../references.qmd#fda-covid-test-delay)
- **Late February:** [CDC tests contaminated, don't work](../references.qmd#cdc-covid-test-contamination-2020)
- **March:** Private labs begging to test, FDA says no
- **Late March:** FDA finally allows other tests
- **Cost:** Unknown thousands of [preventable deaths](../references.qmd#excess-deaths-fda-covid-response)

The FDA's defense: "We were ensuring quality." 
The CDC's tests literally didn't work.
You can't ensure quality of nothing.

## Solutions That Would Work (But Never Will)

**Reciprocal Approval:** If EU/UK/Japan/Canada approves it, we approve it
- Lives saved: Thousands annually
- FDA response: "But their standards might be 0.01% different!"

**Provisional Approval:** Let dying people try experimental drugs
- Current system: Die safely
- Proposed system: Maybe die, maybe live
- FDA logic: Death is preferable to uncertainty

**Outcome-Based Approval:** If it works in real patients, approve it
- Current: Does it work in cherry-picked trial patients?
- Better: Does it work in actual sick humans?
- FDA: "That's not how we've always done it"

## The Bottom Line: Safety Theater

The FDA doesn't make drugs safe.
It makes them:

- Expensive (\$2.6 billion)
- Slow (12+ years)
- Inaccessible (95% of rare diseases have zero treatments)
- Ineffective (tested on wrong populations)

It's security theater but for medicine.
The TSA of healthcare.
Except when TSA fails, your flight is delayed.
When FDA fails, you die.

But at least the bureaucrats are safe from blame.
And isn't that what really matters?

---

*P.S. - The FDA will likely object to this chapter. Estimated time for their formal response: 12-15 years, pending Phase III review.*

---

## A Brief History of Medical Bureaucracy (A Horror Story)

In 1962, some pregnant women took a drug called [thalidomide](../references.qmd#thalidomide-birth-defects) and their babies were born looking like adorable flippers. This was bad.

So Congress, in its infinite wisdom, decided the solution was to make ALL drugs take 17 years to approve and cost [$2.2 billion](../references.qmd#drug-development-costs).

Now instead of occasional flipper babies, we have millions of people dying while waiting for paperwork.

Progress!

The FDA's current system works like this:

1.  Scientists discover a cure for your disease
2.  You wait 17 years
3.  You die
4.  The cure gets approved
5.  Pharmaceutical companies charge your widow $10,000 per pill

It's a beautiful system if you're a mortician or a bankruptcy lawyer.

---

## The Complete List of Stupid Ways the FDA Kills You

### ðŸ’¸ Problem 1: It Costs More Than a Small Country

**[$41,000 per person](../references.qmd#trial-cost-41k)** to test if a pill works.

That's not the pill. That's just to TEST the pill. For that money, you could:

-   Buy a Tesla and crash it into the disease
-   Hire a shaman for a year
-   Fly to Switzerland for assisted dying (much faster)

The total cost to develop one new drug? **[$2.2 billion](../references.qmd#drug-development-costs)**.

That's [more than the GDP of Greenland](../references.qmd#gdp-of-greenland). We could literally buy Greenland and turn it into a giant laboratory for less than it costs to approve one arthritis medication.

### â° Problem 2: Everyone Dies Waiting

**[17 years](../references.qmd#research-to-practice-gap-17-years)** from "Eureka!" to "Take two and call me."

That's:

-   4 presidential terms
-   2 new iPhone models becoming obsolete
-   Your entire child growing up and moving out
-   You dying of whatever the cure was for

During those 17 years, **[21,000 to 120,000 people die](../references.qmd#beta-blocker-deaths)** who didn't have to. That's between a small city and a medium city of corpses. Every decade.

But at least the paperwork is thorough!

### ðŸš« Problem 3: The Velvet Rope of Death

**[85% of sick people](../references.qmd#clinical-trial-exclusions)** aren't allowed in clinical trials.

Why? Because they're too sick. Or not sick enough. Or the wrong kind of sick. Or they live too far from the hospital. Or they're taking other medications. Or they once looked at an aspirin.

It's like having a cure for cancer but only giving it to people who don't have cancer.

Clinical trials have more exclusion criteria than a country club in 1950s Alabama:

-   You can't be too old (might die of being old)
-   You can't be too young (might live too long)
-   You can't be pregnant (fair enough)
-   You can't have other diseases (everyone over 40)
-   You can't be on other medications (everyone with diseases)
-   You must live near a trial site (hope you're rich and urban)
-   You must have exact lab values (measured by angels)

So we test drugs on the 15% of patients who are basically already healthy, then act surprised when the drugs don't work for actual sick people.

Genius!

### ðŸ¦„ Problem 4: Rare Diseases Can Go F*** Themselves

**[95% of rare diseases](../references.qmd#fda-untreated-diseases-95pct)** have ZERO approved treatments.

Why? Math.

If your disease only affects 10,000 people, and it costs $2.2 billion to develop a drug, each patient would need to pay $220,000 just to break even.

So pharmaceutical companies focus on:

-   Erectile dysfunction (affects: half of all men's egos)
-   Baldness (affects: men with money)
-   Wrinkles (affects: women with money)
-   Cholesterol (affects: everyone who eats)

Meanwhile, if you have Exploding Kidney Syndrome affecting 37 people worldwide, the FDA's message is: "Have you tried not having Exploding Kidney Syndrome?"

### ðŸ“Š Problem 5: We Hide Our Failures Like Soviet Russia

**[Half of all clinical trials never publish their results](../references.qmd#publication-bias-clinical-trials)**.

Company: "We tested this drug!"
FDA: "Did it work?"
Company: "...We tested this drug!"

This means we spend billions testing the same failed drugs over and over because nobody admits they failed. It's like playing poker where everyone claims they won but nobody shows their cards.

Pharmaceutical companies bury negative results deeper than Jimmy Hoffa. So other companies waste billions testing the same dead ends.

Your insurance premiums are paying for this stupidity.

### ðŸ§ª Problem 6: The 166 Billion Treatments We're Ignoring

There are **[166 billion potential drug compounds](../references.qmd#166-billion-compounds)** we could test.

Number we've actually tested thoroughly: [About 2,000](../references.qmd#number-of-drugs-tested-thoroughly).

That's like having a library with 166 billion books but only reading the ones with pictures.

At our current rate of testing, we'll have evaluated all possible treatments by the year 3,847,293.

Hope your descendants enjoy the cure for cancer!

### ðŸŽ° Problem 7: The FDA Requires Psychic Powers

Before you can test a drug, you must tell the FDA EXACTLY what it will cure and EXACTLY how you'll measure that cure.

"This drug will reduce depression by 37.2% as measured by the Hamilton Rating Scale on Tuesdays."

What if it cures depression by 90% but only on Wednesdays? Failed trial.
What if it doesn't cure depression but eliminates anxiety? Failed trial.
What if it cures cancer instead? Failed trial, also please report to prison.

It's like requiring Columbus to file a detailed map of America before letting him sail west.
